Karen Pendergrass, Standards Team

This study identifies the vaginal microbiome as a predictor of endometriosis severity, highlighting microbial shifts that correlate with rASRM staging. Anaerococcus emerged as a key biomarker for advanced disease stages, while ST V dominance during menstruation suggests inflammatory shifts. Findings support the potential of non-invasive microbiome-based diagnosis for endometriosis.

This study reveals a distinct microbiome profile in deep endometriosis, with unique bacterial communities in lesion sites, suggesting a role in inflammation and disease progression. Potentially pathogenic genera like Pseudomonas and Alishewanella were abundant, highlighting their possible involvement in endometriotic lesion maintenance and inflammatory responses.

This study maps the microbiota composition along the reproductive tract in endometriosis patients, revealing microbial dysbiosis, reduced Lactobacillus, and increased Pseudomonas and Sphingobium in upper reproductive sites. These findings suggest potential microbial contributions to inflammation, lesion persistence, and new biomarkers for diagnosing endometriosis.

This study identifies gut microbiota and metabolomic shifts in endometriosis, with altered bile acid biosynthesis and LA metabolism. Elevated DCA and DCA levels, coupled with microbial changes, suggest potential biomarkers and therapeutic targets for managing inflammation in endometriosis.

This study identifies microbiome shifts in the lower genital tract of Chinese women with endometriosis, marked by Atopobium enrichment and changes in ribosome biogenesis and immune modulation. Findings suggest potential non-invasive biomarkers and therapeutic targets for endometriosis and adenomyosis.

This study reveals distinct microbiome shifts in the vaginal, cervical, and gut microbiota of women with stage 3/4 endometriosis. The absence of Atopobium and elevated Gardnerella in reproductive sites suggest immune dysregulation, while Shigella dominance in stool samples correlates with bowel involvement, highlighting potential diagnostic biomarkers.

This study shows that antibiotic therapy with metronidazole reduces endometriotic lesion growth and inflammation in mice by targeting the gut microbiota, particularly Bacteroidetes. Findings suggest that microbiota-targeted treatments may offer new therapeutic avenues for endometriosis management.

This study identifies intrauterine microbial colonization in endometriosis, with enriched Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. RHa therapy exacerbated microbial imbalances, highlighting potential therapeutic targets for managing inflammation and infection in endometriosis. Findings suggest microbial modulation may enhance treatment outcomes.

This study found that endometriosis does not induce significant changes in the fecal bacteriota composition during the acute phase of lesion formation. Findings suggest that gut microbial shifts in endometriosis may emerge only during chronic disease stages, highlighting the need for targeted microbiome interventions over prolonged periods.

This study demonstrates that endometriosis induces gut microbiota alterations in a murine model, particularly increasing the Bacteroidetes ratio and enriching Bifidobacterium and Parasutterella. These shifts suggest dysbiosis as a contributing factor to inflammation and immune dysregulation, supporting the potential for microbiota-targeted therapies in endometriosis management.

This study reveals that inflammatory cytokines (L-6, L-10, L-13, and NF-α) are significantly elevated in the peritoneal fluid of endometriosis patients with infertility. These findings suggest their potential role as diagnostic biomarkers and therapeutic targets for managing reproductive complications in endometriosis.

This study identified a microbiome signature in Graves’ disease marked by reduced microbial richness and elevated Prevotella_9 and Haemophilus, with losses in Faecalibacterium and Alistipes, supporting a role for gut dysbiosis in D pathogenesis.

This study found that gut microbiota in Hashimoto’s thyroiditis patients differs markedly from healthy controls, with enriched Escherichia coli and depleted Prevotella. These microbial shifts support the hypothesis that dysbiosis contributes to autoimmune thyroid inflammation and may offer targets for intervention.

This study identified two distinct BS subgroups based on gut microbiome profiles, revealing correlations with regional brain volumes. The findings highlight the role of gut dysbiosis in structural brain alterations, offering potential biomarkers for subtype classification.

BS-like symptoms in Parkinson’s disease are linked to distinct gut microbiota changes, particularly Prevotella depletion, implicating the microbiota-gut-brain axis in non-motor symptoms.

This study reveals that intrauterine microbial colonization is prevalent in women with endometriosis, particularly with Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. Findings suggest that RHa treatment exacerbates microbial colonization, indicating a possible role for targeted antimicrobial therapies in managing endometriosis-associated inflammation.

The study identified distinct oral microbiome profiles in BS patients, particularly in those overweight, highlighting its potential as a non-invasive diagnostic tool for visceral pain severity and symptom progression.

The study identifies significant fecal microbiota dysbiosis in BS patients, marked by increased Pseudomonas aeruginosa and Bacteroides thetaiotamicron, highlighting their potential as microbial biomarkers for BS subtypes.

The study highlights functional dysbiosis in constipated-irritable bowel syndrome, with increased sulfate-reducing bacteria and disrupted CFA profiles.

The study investigated gut microbiota in diarrhea-predominant irritable bowel syndrome (BS), revealing distinct microbial shifts, including increased Enterobacteriaceae and reduced Faecalibacterium populations, indicating potential inflammatory mechanisms

The study identified significant shifts in fecal bile acid composition and gut microbiota in BS-D patients. Elevated primary bile acids and dysbiosis were linked to stool frequency and consistency, suggesting bile acid modulation as a potential therapeutic target for symptom management.

This study found that while probiotics may relieve BS symptoms, they do not revert the gut microbiota imbalances associated with the disorder.

This study reveals that diarrhea-predominant BS (BS) is linked to reduced microbial diversity and niche-specific dysbiosis in the gut.

This study identifies distinct microbiome signatures in pediatric BS, revealing unique microbial imbalances linked to disease subtypes.

This study identifies global microbiota signatures in BS patients, revealing distinct microbial imbalances that differentiate them from healthy controls. Key findings include a 2-fold increase in the Bacteroidetes ratio, reduced Bifidobacterium and Faecalibacterium populations, and significant shifts in methanogens. These alterations suggest potential diagnostic markers and therapeutic targets for BS.

This study reveals that altered microbiota and elevated organic acids in BS patients correlate with increased symptom severity, poorer quality of life, and heightened negative emotions. The findings suggest that microbial shifts leading to increased acetic and propionic acid production play a critical role in the pathophysiology of BS.

This study reveals that BS patients have significantly lower bifidobacteria counts in both fecal and duodenal samples compared to healthy controls. The marked reduction in Bifidobacterium catenulatum levels suggests a critical link to gut dysbiosis, impaired mucosal integrity, and potential contributions to symptom severity in BS subtypes.